In the BioHarmony Drug Report Database

"Preview" Icon

Sunitinib malate

Sutent (sunitinib malate) is a small molecule pharmaceutical. Sunitinib malate was first approved as Sutent on 2006-01-26. It is used to treat gastrointestinal stromal tumors, neuroendocrine tumors, pancreatic neoplasms, and renal cell carcinoma in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors, neuroendocrine tumors, and renal cell carcinoma. It is known to target fibroblast growth factor receptor 1, vascular endothelial growth factor receptor 3, receptor-type tyrosine-protein kinase FLT3, platelet-derived growth factor receptor beta, mast/stem cell growth factor receptor Kit, vascular endothelial growth factor receptor 2, and proto-oncogene tyrosine-protein kinase receptor Ret. Sutent’s patent is valid until 2021-02-15 (FDA).

 

Trade Name

 

Sutent
 

Common Name

 

sunitinib malate
 

ChEMBL ID

 

CHEMBL1567
 

Indication

 

gastrointestinal stromal tumors, neuroendocrine tumors, pancreatic neoplasms, renal cell carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Sunitinib malate structure rendering